Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119558 | 1.00 | USP30 (0.41) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL13179251 | 0.95 | USP30 (0.44) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL883274 | 0.94 | USP30 (0.43) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL883261 | 0.94 | USP30 (0.43) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL883236 | 0.91 | HTT (0.42) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL12682635 | 0.91 | NPSR1 (0.44) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL12682655 | 0.90 | TSHR (0.46) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL10176598 | 0.90 | USP30 (0.41) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL607195 | 0.90 | KMT2A (0.45) | USP30UCHL1ALDH1A1TSHRLMNA | |
| SCHEMBL607196 | 0.90 | KMT2A (0.45) | USP30UCHL1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407445-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20160222034-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8653070-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653070-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407445-B2 | Hepatitis C virus inhibitors | HAVCR2, SLC10A1, EIF2AK2 | USP30 2450/4885UCHL1 2835/4885ALDH1A1 343/4885 |
| US-20160222034-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | USP30 2450/4885UCHL1 2835/4885ALDH1A1 343/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | USP30 2423/4885UCHL1 2831/4885ALDH1A1 365/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | USP30 702/4885UCHL1 3327/4885ALDH1A1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.